Preclinical FLT-PET and FDG-PET imaging of tumor response to the multi-targeted Aurora B kinase inhibitor, TAK-901

Nuclear Medicine and Biology

Volumn 41, Issue 2, 2014, Pages 148-154

  Cullinane, Carleen ^a,d   Waldeck, Kelly L ^a   Binns, David ^a   Bogatyreva, Ekaterina ^a   Bradley, Daniel P ^b   de Jong, Ron ^c   McArthur, Grant A ^a,d   Hicks, Rodney J ^a,d  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

^c Takeda San Diego Inc   (United States)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Aurora B kinase; FDG PET; FLT PET; TAK 901

Indexed keywords

3' [18F]FLUORO 3' DEOXYTHYMIDINE; ANTINEOPLASTIC AGENT; AURORA B KINASE; BETA GALACTOSIDASE; FLUORODEOXYGLUCOSE F 18; HISTONE H3; RADIOPHARMACEUTICAL AGENT; TAK 901; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL METABOLISM; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG RESPONSE; DRUG SCREENING; ENZYME REPRESSION; FEMALE; GLUCOSE METABOLISM; IMAGE ANALYSIS; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; POSITRON EMISSION TOMOGRAPHY;

AURORA B KINASE; FDG-PET; FLT-PET; TAK-901;

ANIMALS; AURORA KINASE B; BIOLOGICAL TRANSPORT; CARBOLINES; COLORECTAL NEOPLASMS; DIDEOXYNUCLEOSIDES; FEMALE; FLUORODEOXYGLUCOSE F18; HCT116 CELLS; HUMANS; MICE; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; SULFONES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84893001268     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2013.11.001     Document Type: Article

References (29)

1. Lee J.J., Kelly W.K. Epothilones: tubulin polymerization as a novel target for prostate cancer therapy. Nat Clin Pract Oncol 2009, 6:85-92.
2. Janssen A., Medema R.H. Mitosis as an anti-cancer target. Oncogene 2011, 30:2799-2809.
3. Teicher B.A. Newer cytotoxic agents: attacking cancer broadly. Clin Cancer Res 2008, 14:1610-1617.
4. Warner S.L., Stephens B.J., Von Hoff D.D. Tubulin-associated proteins: Aurora and Polo-like kinases as therapeutic targets in cancer. Curr Oncol Rep 2008, 10:122-129.
5. Gautschi O., Heighway J., Mack P.C., Purnell P.R., Lara P.N., Gandara D.R. Aurora kinases as anticancer drug targets. Clin Cancer Res 2008, 14:1639-1648.
6. Ruchaud S., Carmena M., Earnshaw W.C. Chromosomal passengers: conducting cell division. Nat Rev Mol Cell Biol 2007, 8:798-812.
7. Keen N., Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004, 4:927-936.
8. Girdler F., Gascoigne K.E., Eyers P.A., et al. Validating Aurora B as an anti-cancer drug target. J Cell Sci 2006, 119:3664-3675.
9. Carvajal R.D., Tse A., Schwartz G.K. Aurora kinases: new targets for cancer therapy. Clin Cancer Res 2006, 12:6869-6875.
10. Dees E.C., Cohen R.B., von Mehren M., et al. Phase 1 Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations. Clin Cancer Res 2012, 18:4775-4784.
11. Cervantes A., Elez E., Roda D., et al. Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res 2012, 18:4764-4774.
12. Farrell P., Shi L., Matuszkiewicz J., et al. Biological Characterization of TAK-901, an Investigational, Novel, Multi-Targeted Aurora B Kinase Inhibitor. Mol Cancer Ther 2013, 12:460-470.
13. Stroobants S., Goeminne J., Seegers M., et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003, 39:2012-2020.
14. Bollag G., Hirth P., Tsai J., et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467:596-599.
15. 18F-fluorothymidine PET/CT as an early predictor of tumor response to treatment with cetuximab in human lung cancer xenografts. Oncol Rep 2011, 26:725-730.
16. Ullrich R.T., Zander T., Neumaier B., et al. Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET). PLoS One 2008, 3:e3908.
17. 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib. Clin Cancer Res 2011, 17:3304-3315.
18. Chan F., Sun C., Perumal M., et al. Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity. Mol Cancer Ther 2007, 6:3147-3157.
19. Dorow D.S., Cullinane C., Conus N., et al. Multi-tracer small animal PET imaging of the tumor response to the novel pan-Erb-B inhibitor CI-1033. Eur J Nucl Med Mol Imaging 2006, 33:441-452.
20. Kim H.J., Cho J.H., Quan H., Kim J.R. Down-regulation of Aurora B kinase induces cellular senescence in human fibroblasts and endothelial cells through a p53-dependent pathway. FEBS Lett 2011, 585:3569-3576.
21. Huck J.J., Zhang M., McDonald A., et al. MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo. Mol Cancer Res 2010, 8:373-384.
22. 18F]fluorothymidine imaging. Clin Cancer Res 2011, 17:1099-1110.
23. Manfredi M.G., Ecsedy J.A., Chakravarty A., et al. Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res 2011, 17:7614-7624.
24. Cass C.E., Dahlig E., Lau E.Y., Lynch T.P., Paterson A.R. Fluctuations in nucleoside uptake and binding of the inhibitor of nucleoside transport, nitrobenzylthioinosine, during the replication cycle of HeLa cells. Cancer Res 1979, 39:1245-1252.
25. Pressacco J., Wiley J.S., Jamieson G.P., Erlichman C., Hedley D.W. Modulation of the equilibrative nucleoside transporter by inhibitors of DNA synthesis. Br J Cancer 1995, 72:939-942.
26. Ritzel M.W., Ng A.M., Yao S.Y., et al. Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). J Biol Chem 2001, 276:2914-2927.
27. Paproski R.J., Wuest M., Jans H.S., et al. Biodistribution and uptake of 3'-deoxy-3'-fluorothymidine in ENT1-knockout mice and in an ENT1-knockdown tumor model. J Nucl Med 2010, 51:1447-1455.
28. 18F-FDG PET of response to Abraxane therapy. J Nucl Med 2011, 52:140-146.
29. Mudd S.R., Holich K.D., Voorbach M.J., et al. Pharmacodynamic evaluation of irinotecan therapy by FDG and FLT PET/CT imaging in a colorectal cancer xenograft model. Mol Imaging Biol 2012, 14:617-624.